Apoptosis and the BCL-2 gene family - Patterns of expression and prognostic value in stage I and II follicular center lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 1, 1999, Pages 19-29

  Logsdon, Mark D ^a   Meyn Jr , Raymond E ^a   Besa, Pelayo C ^a   Pugh, William C ^a   Stephens, L Clifton ^a   Peters, Lester J ^a   Milas, Luka ^a   Cox, James D ^a   Cabanillas, Fernando ^a   Brisbay, Shawn ^a   Andersen, Margret ^a   McDonnell, Timothy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bax; Bcl 2; Bcl x; Follicular center lymphoma

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X;

ADULT; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

ANALYSIS OF VARIANCE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; COHORT STUDIES; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032972659     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00455-6     Document Type: Article

References (64)

1. McDonnell T.J., Meyn R.E., Robertson L.E. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol. 6:1995;53-58.
2. Meyn R.E., Stephens L.C., Ang K.K., et al. Heterogeneity in apoptosis development among irradiated murine tumors of different histologies. Int J Radiat Biol Phys. 64:1993;583-591.
3. Stephens L.C., Hunter N.R., Ang K.K., et al. Apoptosis in irradiated murine tumors. Radiat Res. 127:1991;308-316.
4. Bakhshi A., Jensen J.P., Goldman P., et al. Cloning the chromosomal breakpoint of t(14;18) in human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 41:1985;899-906.
5. Weiss L.M., Warnke R.S., Sklar J., et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 317:1987;1185.
6. Hill M.E., MacLennan K.A., Cunningham D.C., et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma. Blood. 88:1996;1046.
7. Reed J.C., Kitada S., Takayama S., et al. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 5:1994;61-65.
8. Oltvai Z.N., Milliman C.L., Korsemeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
9. Boise L.H., Gonzales-Garcia M., Postema C.E., et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
10. Besa P.C., McLaughlin P.W., Cox J.D., et al. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer. 75:1995;2361-2367.
11. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer. 49:1982;2112-2135.
12. Rappaport H. Tumors of the hematopoietic system In Atlas of tumor pathology . 1966;97-161 Armed Forces Institute of Pathology, Washington DC.
13. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms A proposal from the International Lymphoma Study Group . Blood. 84:1994;1361-1392.
14. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-503.
15. Steel R.G.D., Torrie J.H. Principles and procedures of statistics A biometric approach . 1980;McGraw Hill, New York.
16. Altman D.G. Practical statistics for medical research. 1991;Chapman and Hall, London.
17. Harris E.K., Albert A. Survivorship analysis for clinical studies. 1991;Marcel Dekker, Inc, New York.
18. Mac Manus M.P., Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 14:1996;1282-1290.
19. Gospodarowicz M.K., Sutcliffe S.B., Wells W.A., et al. Results of involved field radiotherapy in clinical stage I-II low grade lymphoma. Int J Radiat Oncol Biol Phys. 227:1992.
20. Vaughan-Hudson B., Vaughan-Hudson G., MacLennan K.A., et al. Clinical stage I non-Hodgkin's lymphoma Long-term follow-up of patients treated by radiotherapy alone as initial therapy . Br J Cancer. 69:1994;1088-1093.
21. Chen M.G., Prosnitz L.R., Gonzalez-Serva A., et al. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer. 43:1979;1245-1254.
22. Tubiana M., Pouillart P., Hayat M., et al. Results of radiotherapy in stage I and II non-Hodgkin's lymphoma. Br J Cancer. 31:1975;402-412.
23. Philips D.L. Radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Clin Radiol. 32:1981;543-546.
24. Mendenhall N., Lynch J. The low-grade lymphomas. Semin Radiat Oncol. 5:1995;254-266.
25. Czader M., Mazur J., Pettersson M., et al. Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas. Cancer. 77:1995;1180-1188.
26. Hollowood K., Macartney J.C. Reduced apoptotic cell death in follicular lymphoma. J Pathol. 163:1991;337-342.
27. Leoncini L., Del Vecchio M.T., Megha T., et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol. 142:1993;755-763.
28. Du M., Singh N., Husseuin A., et al. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue. J Pathol. 178:1996;379-384.
29. Del Vecchio M.T., Leoncini L., Buerki K., et al. Diffuse centrocytic and/or centroblastic malignant non-Hodgkin's lymphomas: Comparison of mitotic and pyknotic (apoptotic) indices. Int J Cancer. 47:1991;38-43.
30. Lipponen P., Aaltomaa S., Kosma V.M., et al. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 30A:1994;2068-2073.
31. Versalainen S., Lipponen P., Talja M., et al. Histological grade, perineural infiltation, tumour-infiltating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 30A:1994;1797-1803.
32. Lipponen P.K., Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 173:1994;333-339.
33. Chyle V., Pollack A., Czerniak B., et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 35:1996;281-287.
34. Tannapfel A., Hahn H.A., Katalinic A., et al. Incidence of apoptosis, cell proliferation, and p53 expression in renal cell carcinomas. Aniticancer Res. 17:1997;1155-1162.
35. Todd D., Yang G., Brown R.W., et al. Apoptosis in renal cell carcinoma Detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors . Hum Pathol. 27:1996;1012-1017.
36. Heatley M.K. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology. 27:1995;469-472.
37. Diebold J., Baretton G., Felchner M., et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol. 105:1996;341-349.
38. Lorenzen J., Lie W.P., Gi G.D., et al. Nasal T/NK cell lymphoma A clinico pathologic study of 30 west Chinese patients with special reference to proliferation and apoptosis . Leuk Lymphoma. 23:1996;593-602.
39. Komaki R., Fujii T., Perkins P., et al. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 36:1996;601-605.
40. Frankfurt O.S., Robb J.A., Sugarbaker E.V., et al. Apoptosis in breast and gastrointestinal carcinomas. Detection in histological sections with monoclonal antibody to single-stranded DNA. Anticancer Res. 16:1996;1979-1988.
41. Levine E.L., Renehan A., Gossiel R., et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol. 37:1995;1-9.
42. Mooy C.M., Luyten G.P., deJong P.T., et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol. 147:1995;1097-1104.
43. Ohashi K., Nemoto T., Eishi Y., et al. Proliferative activity and p53 protein accumulation correlate with early invasive trend, and apoptosis correlates with differentiation grade in oesophageal squamous cell carcinoma. Virchows Arch. 430:1997;107-115.
44. Hamada M., Naomoto Y., Fujiwara T., et al. Suppressed apoptotic induction in esophageal squamous cell carcinomas expressing extensive p53 protein. Jpn J Clin Oncol. 26:1996;398-404.
45. Aihara M., Scardino P.T., Truong L.D., et al. The frequency of apoptosis correlates with the prognosis of gleason grade 3 adenocarcinoma of the prostate. Cancer. 75:1995;522-529.
46. Ngan B., Chen-Levy Z., Weiss L., et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med. 318:1988;1638.
47. Pezzella F., Tse A., Cordell J., et al. Expression of the bcl-2 oncogene protein is not specific for the 14-18 chromosomal translocation. Am J Pathol. 137:1990;225.
48. Cooper K., Haffajee Z. Bcl-2 and p53 protein expression in follicular lymphoma. J Pathol. 182:1997;307-310.
49. Schlaifer D., Krajewski S., Galoin S., et al. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection. Am J Pathol. 149:1996;177-185.
50. Xerri L., Parc P., Brousset P., et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol. 92:1996;900-906.
51. Kang Y.K., Kim C.W., Kim W.H., et al. Primary malignant lymphomas of the stomach. Pathological and clinical analyses of 38 resected cases. J Korean Med Sci. 11:1986;480-488.
52. Grierson H.L., Woolridge T.N., Hell M., et al. Proliferative fraction and DNA content are lower in B-cell non-Hodgkin's lymphomas with the t(14:18). Leuk Lymphoma. 19:1995;253-257.
53. Ashton Key M., Biddolph S.C., Stein H., et al. Heterogeneity of bcl-2 expression in MALT lymphoma. Histopathology. 26:1995;75-78.
54. Johnson A., Brun A., Dictor M., et al. Incidence and prognostic significance of t(14;18) translocation in follicle center cell lymphoma of low and high grade. A report from southern Sweden. Ann Oncol. 6:1995;789-794.
55. Gascoyne R.D., Adomat S.A., Krajewski S., et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 90:1997;244-251.
56. Yunis J.J., Mayer M.G., Arnesen M.A., et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 320:1989;1047-1054.
57. Levine E.G., Arthur D.C., Frizzera G., et al. Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann Int Med. 108:1988;14-20.
58. Pezzella F., Jones M., Ralfkiaer E., et al. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer. 65:1992;87-89.
59. Yin XM, Oltvai ZN, Korsemeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323.
60. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 92:1995;4507-4511.
61. Aguilar-Santelises M., Rottenberg M.E., Lewin N., et al. Bcl-2, bax, and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 69:1996;114-119.
62. Gazzaniga P., Gradilone A., Vercillo R., et al. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer. 69:1996;100-104.
63. Pepper C., Bentley P., Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol. 95:1996;513-517.
64. Sander C.A., Yano T., Clark H.M., et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 82:1993;1994-2004.